Skip to main content
. 2015 Oct 26;62(4):440–447. doi: 10.1093/cid/civ897

Table 2.

Baseline Predictors of Treatment Outcome (SVR12)

Predictors Treatment-Naive Patients
Treatment-Experienced Patients
All Patients
SVR12 (n = 18) No SVR12a (n = 7) P Values SVR12 (n = 20) No SVR12 (n = 5) P Values SVR12 (n = 38) No SVR12b (n = 12) P Values OR (95% CI)
Host factors
 Age, mean, y 55.9 61.0 .02 58.6 59.8 .46 57.3 60.5 .02 0.82 (.68–.99)
 Female, No. (%) 7 (39) 0 (0) .13 8 (40) 2 (40) >.99 15 (39) 2 (17) .18 3.26 (.63–17.01)
 Black, No. (%) 3 (17) 1 (14) >.99 8 (40) 2 (40) >.99 11 (29) 3 (25) >.99 1.22 (.28–5.38)
 BMI, mean, kg/m2 30.3 28.8 .41 31.4 30.7 .80 30.9 29.6 .58 1.03 (.93–1.15)
IL28B CC genotype, No. (%) 3 (17) 2 (29) .60 8 (40) 2 (40) >.99 11 (29) 4 (33) >.99 0.82 (.20–3.27)
IFNL4 TT/TT genotype, No. (%) 1 (5) 0 (0) >.99 1 (5) 0 (0) >.99 2 (5) 0 (0) >.99
 Baseline LDL, mean, mg/dL 83.4 72.6 .37 69.9 40.0 .05 76.3 60.7 .12 1.02 (.99–1.05)
 Baseline hemoglobin A1C, mean, mmol/mol, derived (%) 5.9 5.8 .81 5.9 6.0 .84 5.9 5.9 .98 1.01 (.48–2.12)
 Liver fibrosis score 3, No. (%) 10 (59) 4 (57) >.99 12 (60) 1 (20) .16 22 (59) 5 (42) .28 2.05 (.55–7.70)
 Self-reported nonadherence (≥2 missed doses), No. (%) 3 (17) 2 (29) .60 4 (20) 0 (0) .55 7 (18) 2 (17) >.99 1.13 (.20–6.34)
Viral factors
 HCV genotype 1b, No. (%) 9 (50) 1 (14) .34 2 (10) 0 (0) >.99 11 (29) 1 (8) .25 4.48 (.52–39.01)
 Baseline HCV RNA <6 million IU/mL, No. (%)c 14 (78) 5 (71) >.99 16 (80) 4 (80) >.99 30 (79) 9 (75) >.99 1.25 (.27–5.73)
 Absence of NS3, NS5A, or NS5B RAV with >5-fold resistance, No. (%) 14 (78) 6 (86) >.99 16 (80) 3 (60) .56 30 (79) 9 (75) >.99 1.25 (.27–5.73)

Abbreviations: BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus; LDL, low-density lipoprotein; OR, odds ratio; RAV, resistance-associated variant; SVR12, sustained virologic response at 12 weeks after treatment completion.

a The no-SVR12 group includes 1 patient lost to follow-up and 6 who experienced virologic relapse.

b The no-SVR12 group includes 1 patient lost to follow-up and 11 who experienced virologic relapse.

c By Roche assay.